<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220210053986N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-06</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of  Cavaterm endometrial ablation Vs. hysteroscopic endometrial ablation in treatment of abnormal uterine beeding</public_title>
      <acronym></acronym>
      <scientific_title>Compare of  Cavaterm endometrial ablation Vs. hysteroscopic endometrial ablation in treatment of abnormal uterine beeding</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61890</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly divided into two groups by simple randomization using Excel software and using the RAND function. A column of 100 numbers is created in Excel software containing 50 codes A (cavater group) and 50 codes B (hysteroscopic group). The parallel column contains one hundred random numbers will be generated by the RAND function. After arranging the randomized column while maintaining the connection to the first column, a random sequence is prepared and patients are divided into two groups, respectively.</study_design>
      <phase>3</phase>
      <hc_freetext>Abnormla Uterine Bleeding.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Endometrial ablation by the Cavtherm thermal balloon method: The Cavaterm method is based on the rotation of hot water with a temperature of about 80 ° C at a constant pressure between 240-230 mm Hg in a silicon balloon for 10 minutes. The Cavaterm system consists of a disposable catheter with an adjustable silicone balloon and a central unit. 10 minute treatment is a combination of heat, circulation and also  water pressure to coagulate the endometrium and its underlying myometrial layer in depth of 5 to 9 mm. Intervention 2: Control group: Endometrial ablation by hysteroscopic method: First in the operating room, after filling and emptying and emptying the bladder, uterus, adnexa, is determined by double-handed examination of the touch and position of the uterus. After venting the normal saline and white balance dilating media system with a 4.5 mm diagnostic hysteroscope, the uterine cavity was examined in all directions. In the absence of a problem, the lower valve of the vagina is inserted and the anterior edge of the cervix is ​​closed with a tenaculum, and uterine curettage is performed in all directions. After re-ventilation and performing white balance, it enters the endometrial cavity and the endometrial cavity is coagulated with a hysteroscope with a power of 50-150 watts, depending on the size of the electrode, depending on the size of the electrode and coagulation. The lateral and eventually the posterior wall is destroyed. In this method, during the destruction, it is activated only when the electrode moves towards the surgeon, at the same time, it tries to avoid the destruction of the cervical mucosa.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The study is a student thesis and its intellectual property is with Iran University of Medical Sciences.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sepideh Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Akbarabadi hospital, Baghferdous station, Molavi st.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 21 5560 6034</telephone>
        <email>sepidehazizi.azizi@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahdis Mohammadian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Akbarabadi hospital, Baghferdous station, Molavi st.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1168743514</zip>
        <telephone>+98 912 003 0255</telephone>
        <email>Amiri_mahdis@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Non nullipar women in the age range between 35-55
Abnormal uterine bleeding (AUB)
Lack of proper response to medical treatment
Not trying to conceeve more
Unwillingness to hystrectomy</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>55 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Malignancy which confirmed  in pathology (Curretage or piple biopsy sample)
Grade 0 &amp; 1 submucosal myoma in sonography
Uterine cavity distortion
Uterine size &gt; 20 weeks</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N93</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other abnormal uterine and vaginal bleeding</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Endometrial ablation by the Cavtherm thermal balloon method: The Cavaterm method is based on the rotation of hot water with a temperature of about 80 ° C at a constant pressure between 240-230 mm Hg in a silicon balloon for 10 minutes. The Cavaterm system consists of a disposable catheter with an adjustable silicone balloon and a central unit. 10 minute treatment is a combination of heat, circulation and also  water pressure to coagulate the endometrium and its underlying myometrial layer in depth of 5 to 9 mm.</i_keyword>
      <i_keyword>Control group: Endometrial ablation by hysteroscopic method: First in the operating room, after filling and emptying and emptying the bladder, uterus, adnexa, is determined by double-handed examination of the touch and position of the uterus. After venting the normal saline and white balance dilating media system with a 4.5 mm diagnostic hysteroscope, the uterine cavity was examined in all directions. In the absence of a problem, the lower valve of the vagina is inserted and the anterior edge of the cervix is ​​closed with a tenaculum, and uterine curettage is performed in all directions. After re-ventilation and performing white balance, it enters the endometrial cavity and the endometrial cavity is coagulated with a hysteroscope with a power of 50-150 watts, depending on the size of the electrode, depending on the size of the electrode and coagulation. The lateral and eventually the posterior wall is destroyed. In this method, during the destruction, it is activated only when the electrode moves towards the surgeon, at the same time, it tries to avoid the destruction of the cervical mucosa.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Amenorhea incidence. Timepoint: Months 3,6 and 12 after surgery. Method of measurement: Clinical history.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Need to hystrectomy. Timepoint: Months 3, 6 and 12 after surgery. Method of measurement: Clinical history.</sec_outcome>
      <sec_outcome>Menstraul bleeding severity. Timepoint: Months 3,6 and 12 after surgery. Method of measurement: Days of menstraul bleeding and number of used menstrual pads.</sec_outcome>
      <sec_outcome>Satisfaction after surgery. Timepoint: Months 3,6 and 12 after surgery. Method of measurement: Likert scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-29</approval_date>
        <contact_name>Research Ethics Committee of School of Medicine, IUMS</contact_name>
        <contact_address>Hemmat exp.way Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
